8-Hydroxy-2′-deoxyguanosine and arsenic compounds in urine and serum of a 4-year-old child suffering from acute promyelocytic leukemia during treatment with arsenic trioxide

Forensic Toxicology

Volumn 29, Issue 1, 2011, Pages 65-68

  Fujihara, Junko ^a   Hasegawa, Masanori ^b   Kanai, Rie ^a   Agusa, Tetsuro ^a   Iwata, Hisato ^c   Tanabe, Shinsuke ^c   Yasuda, Toshihiro ^d   Yamaguchi, Seiji ^a   Takeshita, Haruo ^a  

^a SHIMANE UNIVERSITY   (Japan)

^b Criminal Investigation Laboratory   (Japan)

^c EHIME UNIVERSITY   (Japan)

^d UNIVERSITY OF FUKUI   (Japan)

Author keywords

8 OHdG; Acute promyelocytic leukemia; Arsenic compounds; Arsenic trioxide; Child patient; Dimethylarsinic acid

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ARSENIC; ARSENIC TRIOXIDE; CACODYLIC ACID; METHANEARSONIC ACID; RETINOIC ACID;

ARTICLE; BLOOD SAMPLING; CASE REPORT; CHILD; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG METABOLISM; DRUG URINE LEVEL; FEMALE; HUMAN; METAL METABOLISM; PRESCHOOL CHILD; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; URINALYSIS;

EID: 79251621672     PISSN: 18608965     EISSN: 18608973     Source Type: Journal    
DOI: 10.1007/s11419-010-0104-z     Document Type: Article

References (15)

1. K Minakata H Nozawa I Yamagishi K Gonmori S Kanno K Watanabe M Suzuki WHA Ahmed O Suzuki 2009 Sensitive determination of arsenite and arsenate in plasma by electrospray ionization tandem mass spectrometry after chelate formation Forensic Toxicol 27 37 40 1:CAS:528:DC%2BD1MXitlGgtL4%3D 10.1007/s11419-008- 0064-8
2. 3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins Blood 88 1052 1061 1:CAS:528:DyaK28Xks1Cjur0%3D 8704214
3. D Douer MS Tallman 2005 Arsenic trioxide: new clinical experience with an old medication in hematological malignancies J Clin Oncol 23 2396 2410 1:CAS:528:DC%2BD2MXjsVyhsrk%3D 10.1200/JCO.2005.10.217 15800332 (Pubitemid 46218734)
4. M Vahter 1994 Species differences in the metabolism of arsenic compounds Appl Organomet Chem 8 175 182 1:CAS:528:DyaK2cXkslGns70%3D 10.1002/aoc.590080304
5. JP Buchet R Lauwerys H Roels 1981 Urinary excretion of inorganic arsenic and its metabolites after repeated ingestion of sodium metaarsenite by volunteers Int Arch Occup Environ Health 48 111 118 1:CAS:528:DyaL3MXkslCrtLw%3D 10.1007/BF00378431 6894910 (Pubitemid 11121113)
6. Z Wang J Zhou X Lu Z Gong XC Le 2004 Arsenic speciation in urine from acute promyelocytic leukemia patients undergoing arsenic trioxide treatment Chem Res Toxicol 17 95 103 1:CAS:528:DC%2BD3sXpvFKhurw%3D 10.1021/tx0341714 14727923 (Pubitemid 38134064)
7. Y Fukai M Hirata M Ueno N Ichikawa H Kobayashi S Hiroshi T Sakurai K Kinoshita T Kaise S Ohta 2006 Clinical pharmacokinetic study of arsenic trioxide in an acute promyelocytic leukemia (APL) patient: speciation of arsenic metabolites in serum and urine Biol Pharm Bull 29 1022 1027 1:CAS:528: DC%2BD28Xmt1ehtb8%3D 10.1248/bpb.29.1022 16651738
8. J Fujihara T Agusa J Tanaka Y Fujii T Moritani M Hasegawa H Iwata S Tanabe H Takeshita 2009 8-Hydroxy-2′-deoxyguanosine (8-OHdG) as a possible marker of arsenic poisoning: a clinical case study on the relationship between concentrations of 8-OHdG and each arsenic compound in urine of an acute promyelocytic leukemia patient being treated with arsenic trioxide Forensic Toxicol 27 41 44 10.1007/s11419-008-0062-x
9. WC Chou C Jie AA Kenedy RJ Jones MA Trush CV Dang 2004 Role of NADPH oxidase in arsenic-induced reactive oxygen species formation and cytotoxicity in myeloid leukemia cells Proc Natl Acad Sci USA 101 4578 4583 1:CAS:528:DC%2BD2cXjtFKis7g%3D 10.1073/pnas.0306687101 15070760 (Pubitemid 38437453)
10. M Honda Y Yamada M Tomonaga H Ichinose S Kamihira 2000 Correlation of urinary 8-hydroxy-2′-deoxyguanosine (8-OHdG), a biomarker of oxidative DNA damage, and clinical features of hematological disorders: a pilot study Leuk Res 24 461 468 1:CAS:528:DC%2BD3cXislehtb0%3D 10.1016/S0145-2126(00)00006-0 10781678 (Pubitemid 30227222)
11. E Fox BI Razzouk BC Widemann S Xiao M O'Brien W Goodspeed GH Reaman SM Blaney AJ Murgo FM Balis PC Adamson 2008 Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma Blood 111 566 573 1:CAS:528:DC%2BD1cXns1CgtA%3D%3D 10.1182/blood-2007-08-107839 17959855
12. G Quezada L Kopp E Estey RJ Wells 2008 All-trans-retinoic acid and arsenic trioxide as initial therapy for acute promyelocytic leukemia Pediatr Blood Cancer 51 133 135 10.1002/pbc.21529 18293388 (Pubitemid 351717406)
13. S Fujisawa R Ohno K Shigeno N Sahara S Nakamura K Naito M Kobayashi K Shinjo A Takeshita Y Suzuki H Hashimoto K Kinoshita M Shimoya T Kaise K Ohnishi 2007 Pharmacokinetics of arsenic species in Japanese patients with relapsed or refractory acute promyelocytic leukemia treated with arsenic trioxide Cancer Chemother Pharmacol 59 485 493 1:CAS:528:DC%2BD2sXlslahuw%3D%3D 10.1007/s00280-006-0288-4 16937107 (Pubitemid 46122327)
14. M Ninomiya T Kajiguchi K Yamamoto T Kinoshita N Emi T Naoe 2006 Increased oxidative DNA products in patients with acute promyelocytic leukemia during arsenic therapy Haematologica 91 1571 1572 1:CAS:528:DC%2BD28XhtlSltbzF 17082016
15. S Kimura H Yamauchi Y Hibino M Iwamoto K Sera K Ogino 2006 Evaluation of urinary 8-hydroxydeoxyguanine in healthy Japanese people Basic Clin Pharmacol Toxicol 98 496 502 1:CAS:528:DC%2BD28XltVyru70%3D 10.1111/j.1742-7843.2006.pto- 217.x 16635109